Trastuzumab (Herceptin; Genetech, San Francisco, CA, USA) is designed to target the extra-cellular domain of human epidermal growth factor receptor 2 (HER2) and block its function, and is currently used in patients with early stage and metastatic HER2-positive breast and gastric cancers. Here, ERBB2 is linked to gastric cancer.